Ayala Pharmaceuticals Inc. (AYLA) NASDAQ
$0.50 - (-)
Market Cap: -
As of 01/18/23 12:00 AM EST. Market closed.
Ayala Pharmaceuticals Inc. (AYLA)
NASDAQ
$0.50
- (-)
Market Cap: -
As of 01/18/23 12:00 AM EST. Market closed.
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted ... read more
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE). read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
SIDRANSKY DAVID | Director | May 12, 2020 | Buy | $15.02 | 25 | 376 | 225 | Mar 08, 2021, 04:15 PM |
SIDRANSKY DAVID | Director | Dec 23, 2020 | Buy | $11.56 | 4 | 46 | 250 | Mar 08, 2021, 04:15 PM |
SIDRANSKY DAVID | Director | May 08, 2020 | Buy | $15.27 | 200 | 3,054 | 200 | Mar 08, 2021, 04:15 PM |
SIDRANSKY DAVID | Director | Sep 14, 2020 | Buy | $10.70 | 1 | 11 | 246 | Mar 08, 2021, 04:15 PM |
SIDRANSKY DAVID | Director | Sep 11, 2020 | Buy | $10.07 | 10 | 101 | 245 | Mar 08, 2021, 04:15 PM |
SIDRANSKY DAVID | Director | Aug 14, 2020 | Buy | $11.07 | 5 | 55 | 235 | Mar 08, 2021, 04:15 PM |
SIDRANSKY DAVID | Director | Jul 17, 2020 | Buy | $11.86 | 4 | 47 | 230 | Mar 08, 2021, 04:15 PM |
SIDRANSKY DAVID | Director | Jul 07, 2020 | Buy | $9.60 | 1 | 10 | 226 | Mar 08, 2021, 04:15 PM |
Gordon Gary B. | Chief Medical Officer | Feb 24, 2021 | Option Exercise | $5.16 | 3,000 | 15,480 | 11,520 | Feb 26, 2021, 05:47 PM |
Gordon Gary B. | Chief Medical Officer | Feb 24, 2021 | Sale | $17.46 | 3,000 | 52,385 | 8,520 | Feb 26, 2021, 05:47 PM |
Mamluk Roni | President & CEO | Feb 22, 2021 | Sale | $19.86 | 15,200 | 301,813 | 163,271 | Feb 24, 2021, 05:42 PM |
Mamluk Roni | President & CEO | Feb 24, 2021 | Sale | $17.40 | 10,800 | 187,919 | 145,345 | Feb 24, 2021, 05:42 PM |
Mamluk Roni | President & CEO | Feb 23, 2021 | Sale | $17.89 | 7,126 | 127,483 | 156,145 | Feb 24, 2021, 05:42 PM |
Mamluk Roni | President & CEO | Jan 21, 2021 | Sale | $15.04 | 1,406 | 21,147 | 178,471 | Jan 22, 2021, 04:05 PM |
Mamluk Roni | President & CEO | Jan 20, 2021 | Sale | $15.03 | 19,466 | 292,533 | 179,877 | Jan 22, 2021, 04:05 PM |
Gordon Gary B. | Chief Medical Officer | Jan 20, 2021 | Option Exercise | $5.16 | 3,000 | 15,480 | 11,520 | Jan 22, 2021, 04:05 PM |
Gordon Gary B. | Chief Medical Officer | Jan 20, 2021 | Sale | $15.03 | 3,000 | 45,084 | 8,520 | Jan 22, 2021, 04:05 PM |
Harel Insurance Co LTD | 10% Owner | May 12, 2020 | Buy | $15.00 | 550,000 | 8,250,000 | 2,163,834 | May 14, 2020, 08:30 PM |
Israel Biotech Fund I, L.P. | 10% Owner | May 12, 2020 | Buy | $15.00 | 225,000 | 3,375,000 | 3,315,119 | May 14, 2020, 04:41 PM |
aMoon 2 Fund Limited Partnership | 10% Owner | May 12, 2020 | Buy | $15.00 | 800,000 | 12,000,000 | 2,991,473 | May 14, 2020, 04:31 PM |
Owner | Relationship | Date | Value($) |
SIDRANSKY DAVID | Director | 05/12/2020 | 376 |
SIDRANSKY DAVID | Director | 12/23/2020 | 46 |
SIDRANSKY DAVID | Director | 05/08/2020 | 3,054 |
SIDRANSKY DAVID | Director | 09/14/2020 | 11 |
SIDRANSKY DAVID | Director | 09/11/2020 | 101 |
SIDRANSKY DAVID | Director | 08/14/2020 | 55 |
SIDRANSKY DAVID | Director | 07/17/2020 | 47 |
SIDRANSKY DAVID | Director | 07/07/2020 | 10 |
Gordon Gary B. | Chief Medical Officer | 02/24/2021 | 15,480 |
Gordon Gary B. | Chief Medical Officer | 02/24/2021 | 52,385 |
Mamluk Roni | President & CEO | 02/22/2021 | 301,813 |
Mamluk Roni | President & CEO | 02/24/2021 | 187,919 |
Mamluk Roni | President & CEO | 02/23/2021 | 127,483 |
Mamluk Roni | President & CEO | 01/21/2021 | 21,147 |
Mamluk Roni | President & CEO | 01/20/2021 | 292,533 |
Gordon Gary B. | Chief Medical Officer | 01/20/2021 | 15,480 |
Gordon Gary B. | Chief Medical Officer | 01/20/2021 | 45,084 |
Harel Insurance Co LTD | 10% Owner | 05/12/2020 | 8,250,000 |
Israel Biotech Fund I, L.P. | 10% Owner | 05/12/2020 | 3,375,000 |
aMoon 2 Fund Limited Partnership | 10% Owner | 05/12/2020 | 12,000,000 |